Shares of IceCure Medical jumped 8.1% to $3.47 after the Israel-based medtech company announced that Adventist Health Glendale became the first hospital cleared to enroll patients in its post-marketing ChoICE study — a critical step in proving its tumor-freezing technology works in routine clinical settings and not just in controlled trials.
The First Patient-Enrollment Site Turns a Regulatory Box-Check Into a Sales Funnel. IceCure's device, which destroys breast tumors by freezing them instead of surgically removing them, received FDA authorization in October 2025 for women 70 and older with low-risk tumors no larger than 1.5 centimeters. The FDA mandated a post-marketing study as a condition. The ChoICE study will enroll up to 400 patients across multiple U.S. sites, gathering real-world data to support further clinical adoption. Crucially, clinical study sites may offer the cryoablation procedure to additional patients not enrolled in the study, supporting broader commercial adoption — meaning every site activated doubles as a paying customer.
One Hospital Down, Twenty-Nine to Go — and the Clock Is Ticking. The study is expected to enroll approximately 400 patients across 30 clinical sites within 36 months,
with at least 80 patients expected in the first year. Adventist Health Glendale — a 515-bed tertiary care hospital — lends credibility but is still just site number one. The pace at which IceCure signs up the remaining 29 sites will determine whether enrollment targets survive contact with reality.
The Balance Sheet Leaves Almost No Room for Delay. Q1 2026 revenue climbed 26% to $911,000, while net loss widened to $4.3 million and cash stood at $8.1 million.
Active U.S. accounts increased 46% to 19. But the math is stark: at the current burn rate, the company has roughly two quarters of cash remaining. An effective shelf registration filed in March allows IceCure to offer up to $100 million in shares, warrants, or units, practically guaranteeing further dilution for existing shareholders.
The Larger Question: Narrative vs. Numbers. A limited FDA indication and protracted reimbursement timeline pose significant challenges to achieving the aggressive revenue growth needed for breakeven, which analysts don't expect until around 2028. The stock trades at a market cap near $15 million against trailing revenue of roughly $3.4 million — cheap if you believe adoption will accelerate, but expensive for a company that may need to sell shares just to keep the lights on. The first ChoICE site is a legitimate milestone. Whether it is an inflection point depends entirely on what follows.